AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03247101
Drug: Urso group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodoxycholic acid, 200mg po tid x 6 months
Trial: NCT03247101
Drug: Biotase group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
Trial: NCT01944085
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup
Trial: NCT01944085
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Syrup
Trial: NCT00497497
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00497497
Drug: PRO95780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00674102
Drug: ASA404
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01168596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
Trial: NCT00794430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, bid, for 13 weeks
Trial: NCT00123630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given IV once every 2-4 weeks based on weight
Trial: NCT01910155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03386162
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
Trial: NCT03699202
Drug: AK0529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
Trial: NCT03699202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
Trial: NCT02150707
Drug: Dipeptidyl-Peptidase IV Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
Trial: NCT00841815
Drug: Norvasc®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Tablet
Trial: NCT00781261
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
Trial: NCT00781261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the control group will receive a placebo drug for a similar period
Trial: NCT00005980
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03578055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
Trial: NCT00009178
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00809822
Drug: NPB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin
Trial: NCT00809822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline
Trial: NCT02071615
Drug: caffein 200mg tablet given once by mouth
RxNorm normalized name: caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-arm, single-drug dosage comparison study
Trial: NCT02071615
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04626726
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/㎡ for D-3 and D-2
Trial: NCT00928668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo device for comparison
Trial: NCT05085834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules once daily
Trial: NCT02314793
Drug: ASP2205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02314793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01416337
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg single dose tablet on Day 1 of study
Trial: NCT01416337
Drug: GSK1120212B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single administration of a slow 1 minute IV push on Day 1.
Trial: NCT01836757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01417767
Drug: CHG regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
Trial: NCT03198403
Drug: Bupivacaine-epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
Trial: NCT00199927
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
Trial: NCT00199927
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy
Trial: NCT02720757
Drug: Spiolto Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide + Olodaterol
Trial: NCT01230411
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg ibuprofen in 250 cc saline administered IV
Trial: NCT01761149
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
Trial: NCT02427932
Drug: Ampicillin and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
Trial: NCT02427932
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescribed to non-pregnant participants
Trial: NCT00420511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once a day
Trial: NCT03616340
Drug: Shoulder injection
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra articular or subacromial shoulder injection
Trial: NCT03616340
Drug: knee injection
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-articular knee injection
Trial: NCT02499237
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
Trial: NCT00157872
Drug: MK0966; rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00157872
Drug: Comparator: naproxen tablet 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02908100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
Trial: NCT04446052
Drug: GM-CSF priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04446052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01085903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
Trial: NCT02296099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
Trial: NCT02971839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02085863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
Trial: NCT02429960
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
Trial: NCT01212900
Drug: Statins, HMG CoA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy
Trial: NCT00278161
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg/day on Days 15, 16, 17, and 18.
Trial: NCT00865748
Drug: CLUCOPHAGE® XR 500 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Trial: NCT01418456
Drug: antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
Trial: NCT00548886
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
Trial: NCT00950521
Drug: convention therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiplatelet
Trial: NCT00355043
Drug: Zinc sulphate 20 mg
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03379974
Drug: DDAVP Inhalant Product
RxNorm normalized name: DDAVP Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
Trial: NCT01115504
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg daily for 30 days
Trial: NCT04669795
Drug: Cissus Quadrangularis
RxNorm normalized name: Cissus quadrangularis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
Trial: NCT02487186
Drug: Doxicicline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
Trial: NCT00687076
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
Trial: NCT00822094
Drug: Intensive Salvage Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02644551
Drug: CELEXT07
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00647647
Drug: Lamisil® Tablets 250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg, single dose fasting
Trial: NCT02477748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet PO, taken once daily for 10 weeks.
Trial: NCT00284128
Drug: AVE7688
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration (capsules)
Trial: NCT01021527
Drug: Comparator: Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration of exenatide 5ug by subcutaneous injection
Trial: NCT01021527
Drug: Comparator: Treatment C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration of exenatide 10ug by subcutaneous injection
Trial: NCT02892370
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 tablets (10 mg)
Trial: NCT00679614
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
Trial: NCT03884673
Drug: DTG+ 3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
Trial: NCT00633685
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
Trial: NCT00633685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
Trial: NCT01524406
Drug: HPP593
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, twice a day.
Trial: NCT01524406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, twice a day.
Trial: NCT01862003
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
Trial: NCT01862003
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
Trial: NCT01862003
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
Trial: NCT02137343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02137343
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Trial: NCT03017001
Drug: intravenous w-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B 3.0% formulation, gel, topically, once a week for 1 cycle.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B 3.0% formulation, gel, topically, once a week for 2 cycles.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B placebo-matching gel, topically, once a week for 1 cycle.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B placebo-matching gel, topically, twice a week for 1 cycle.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B placebo-matching gel, topically, once a week for 2 cycles.
Trial: NCT00312286
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B placebo-matching gel, topically, twice a week for 2 cycles.
Trial: NCT01483170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo fexinidazole
Trial: NCT03765931
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
Trial: NCT02880319
Drug: Stereotactic Body Radiation Therapy (SBRT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02090764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04684420
Drug: Glucophage® XR RM Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.
Trial: NCT04684420
Drug: Glucophage® XR Reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
Trial: NCT00651287
Drug: quinapril 20 mg plus hydrochlorothiazide 12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
Trial: NCT02327169
Drug: MLN2480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN2480 tablets.
Trial: NCT02327169
Drug: MLN0128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN0128 capsules.
Trial: NCT01047540
Drug: AIC316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01047540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02836249
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF 25 mg tablet administered orally once daily
Trial: NCT02836249
Drug: TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF placebo tablet administered orally once daily